Maker of implantable collamer lenses (ICLs), a surgical alternative to LASIK for correcting vision, especially in myopia.
Maker of implantable collamer lenses (ICLs), a surgical alternative to LASIK for correcting vision, especially in myopia.
The lens is a one-time implant per eye, so sales depend on bringing in new patients through surgeon training and consumer demand rather than repeat purchases. China is its largest market, where patients pay privately, so economic sentiment and local competition matter.
Moat: narrow (IP / patents, brand, regulatory licence). Proprietary Collamer lens material and long track record differentiate ICL from newer competitors.
Headquarters: Lake Forest, California · Founded: 1982 · Employees: 957
Size STAAR Surgical (STAA) is a United States Health Care company (Medical Specialties) with a market value of $1.27B, the 2081st largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.35 on 18 Nov 2026.
Performance Over six months the shares fell 23.3%, against -14.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 42.4% over the last twelve months (peer median +10.8%); the operating margin is 6.7% (peer median 15.3%).
Valuation It trades at 46.9× forward earnings against a peer median of 23.9× (2nd most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.5 points below its cost of capital (11.0% WACC).
Short interest Short interest is 7.3% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $328M | $239M | $314M | $322M | $284M |
| Revenue growth | — | -24% | -3% | +13% | — |
| Gross profit | $234M | $177M | $235M | $253M | $223M |
| EBITDA | $33.1M | -$37.2M | -$5.72M | $33.2M | $48.3M |
| Net income | $530,000 | -$80.4M | -$20.2M | $21.3M | $39.7M |
| Free cash flow | $17.8M | -$40.0M | -$7.67M | -$3.59M | $17.6M |
| Capital expenditure | $3.55M | $5.82M | $23.4M | $18.2M | $18.1M |
| Total debt | $33.6M | $38.4M | $38.7M | $35.8M | $31.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| STAAR Surgical STAA | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STAA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.6% | -5.1% | 2nd highest of 21 |
| 6-month return | -23.3% | -14.3% | 8th lowest of 20 |
| Distance from 52-week high | -29.3% | -39.9% | 6th highest of 21 |
| Revenue growth (TTM) | +42.4% | +10.8% | 2nd highest of 19 |
| Operating margin | 6.7% | 15.3% | 10th lowest of 20 |
| Forward P/E | 46.9× | 23.9× | 2nd most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 35.1% | 10.3% | most demanding of 12 |
| Growth delivered (Del g) | +7.9% | +16.5% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | +27.2 pp | -8.1 pp | most demanding of 12 |
| ROIC minus cost of capital | -2.5 pp | +0.9 pp | 8th lowest of 20 |
| EV / EBITDA | 33.2× | 12.3× | most expensive of 6 |
| Net debt / EBITDA | -5.2× | -0.9× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |